Lupin launches generic Synthroid
Lupin is introducing its generic Synthroid (levothyroxine sodium tablets), which previously was approved by the Food and Drug Administration.
Lupin’s product is the generic of AbbVie’s Synthroid tablets.
It is indicated as replacement therapy in primary, secondary and tertiary congenital or acquired hypothyroidism, as well as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
The product had a market value of about $2.5 billion, according to January 2019 IQVIA data.
Lupin’s product is the generic of AbbVie’s Synthroid tablets.
It is indicated as replacement therapy in primary, secondary and tertiary congenital or acquired hypothyroidism, as well as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
The product had a market value of about $2.5 billion, according to January 2019 IQVIA data.